NeoGenomics NEO 深 沪
等待开盘 12-19 09:30:00 美东时间
11.68
+0.050
+0.43%
华盛通- 最 高11.89
- 今 开11.75
- 成交量 221.59万股
- 最 低 11.58
- 昨 收 11.63
- 总市值 15.07亿
- 52周最高 19.115
- 市盈率 静 --
- 换手率 1.72%
- 52周最低 4.72
- 委 比 -84.34%
- 总股本 1.29亿
- 历史最高 61.57
- 量 比 1.44
- 振 幅 2.67%
- 历史最低 0.96
- 每 手 1
- 风险率 2.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natera Ends Lawsuit, Clearing Path for NeoGenomics' RaDaR ST Launch
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its
12-15 20:24
NeoGenomics Data At ASH 2025 Shows Comprehensive Genomic Profiling Improves Diagnosis And Identifies Actionable Fusions In Myeloid Malignancies
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and
12-08 21:08
Natera Buys Foresight To Boost Super-Early Cancer Detection Tech
Natera acquires Foresight Diagnostics for $275 million upfront with potential for $175 million in earnouts.
12-05 23:05
Earnings Scheduled For November 14, 2025
Companies Reporting Before The Bell • Inhibrx Biosciences (NASDAQ:INBX) is expe...
11-14 19:11
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
10-28 19:11
NeoGenomics Affirms FY2025 Adj EPS Guidance of $0.08-$0.12 vs $0.09 Est
NeoGenomics (NASDAQ:NEO) affirms FY2025 Adj EPS guidance from $0.08-$0.12 to $0.08-$0.12 vs $0.09 analyst estimate..
10-28 19:07
NeoGenomics Q3 Adj. EPS $0.03 Beats $0.02 Estimate, Sales $187.797M Beat $183.770M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.02 by 42.86 percent. This is a 40 percent decrease over earnings of $0.05 per share from the same
10-28 19:05
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
NeOnc Technologies Holdings, Inc. (NeOnc) announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will become the Executive Chairman of NuroMENA Holdings Ltd., the Middle East subsidiary of NeOnc, which focuses on developing treatments for brain cancer and other CNS malignancies. This partnership underscores the UAE's commitment to addressing global health challenges and aligns with Sheikh Nahyan's humanitarian vision. NeOnc's NEO™ platform...
10-28 13:00
PayPal to integrate Mastercard's agentic payments platform into its wallet
PayPal Holdings (NASDAQ:PYPL) (NEOE:PYPL:CA) and Mastercard (NYSE:MA) are expanding their long-standing partnership with the integration of the latter's agentic payments platform to PayPal's wallet. P...
10-27 20:55
